AzTrials
AzTrials

Male InfertilityCROSPNCT05383599

Characterization of Sperm Population Following Different Selection Procedures

An observational study of Male Infertility, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The present study aims to determine which of the sperm selection techniques used in IVF (In Vitro Fertilization) laboratory leads to selection of the best/healthiest sperm population based on their morpho-functional parameters. Read more about this study

Who is it for?
Any age, men only
Conditions the study is for
Male Infertility
How many people
50 participants
Where
1 siteBelgium
Study dates
16 Jul 2022to 1 Aug 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Men only
  • Child, Adult, Older adult

Study population: Unused raw semen samples after diagnostic tests will be included in the study if they fulfil the inclusion criteria

Who may be able to join

  • semen volume ≥1.5ml
  • sperm concentration >20 x 106 spermatozoa/ml
  • ≥30% progressive motility

Who cannot join

  • semen samples processed for immediate or later use in Assisted Reproductive Medicine

Trial locations and contacts

1 site in 1 country.

Belgium1 site, 1 recruiting
  • UZ Brussel CRG

    Brussels, 1090

    Ileana G Mateizel, PhD

    Recruiting

Other trials in Belgium

About this study

The present study aims to determine which of the sperm selection techniques used in IVF (In Vitro Fertilization) laboratory leads to selection of the best/healthiest sperm population based on their morpho-functional parameters. Different procedures are currently used in our laboratory to select the sperm population that will be used to inseminate the oocytes: Density Gradient Centrifugation (DGC), DGC in combination with Magnetic Activated Sperm Sorting (MACS), and Microfluidic Sperm Sorting (MSS). The sperm cells selected by these techniques will be evaluated for specific morpho-functional features such as, motility, morphological abnormalities, and apoptotic status [phosphatidylserine translocation (early stages of apoptosis)] and DNA (Deoxyribonucleic Acid) fragmentation as an indicator of stages of apoptosis.

Read the detailed description

Different procedures are currently available to select the sperm population that will be used to inseminate the oocytes during Medical Assisted Reproduction (MAR). The selected population should contain fully functional spermatozoa that possess the ability to reach the fertilization site and allow optimal fertilization and embryo development. These abilities are strictly dependent on specific sperm morpho-functional features such as, but not limited to, motility, morphological abnormalities, apoptotic status [phosphatidylserine translocation (early stages of apoptosis)] and DNA fragmentation (later stages of apoptosis), The present study aims to determine which of the sperm selection techniques used in our IVF laboratory lead to selection of the best/healthy sperm population based on their morpho-functional parameters. For this purpose, unused raw semen after routine diagnostic analysis will be split in 3 fractions and will be processed immediately by different sperm preparation methods: 1) DGC, 2) DGC and MACS, and 3) MSS.

The sperm cells selected by each method will be analyzed for morphological and functional parameters.

Initial sperm concentration (×106/ml) will be assessed using a counting chamber.

Sperm motility will be evaluated on 200 spermatozoa under 40× magnifications and the results will be expressed as percentages.

After each selection procedure, concentration and motility will be determined with the use of a Neubauer counting chamber.

Spermatozoa with normal morphology will be checked on smears stained using Diff Quick Staining on dried smears, 200 spermatozoa will be classified as normal/abnormal according to Kruger strict criteria.

Phosphatidylserine (PS) translocation (early apoptotic marker): will be analyzed using fluorescence microscopy following sperm cell suspension incubation with Annexin V-FITC (Fluorescein Isothiocyanate) and propidium iodide (PI). The spermatozoa will be classified as: viable spermatozoa without PS translocation (PI negative/Annexin negative); viable with translocated PS (PI negative/Annexin positive); dead (PI positive/Annexin positive or PI positive/Annexin negative).

DNA fragmentation index (percentage of sperm cells showing DNA fragmentation per number of cells analyzed; DFI) will be analyzed using terminal deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate-fluorescein nick end labeling (TUNEL) assay protocol (commercially available kit "In Situ Cell Death Detection"; Roche Diagnostic). The cleavage of genomic DNA during apoptosis leads to both single-strand breaks (nicks) and double-stranded, low-molecular-weight DNA fragments. These DNA strand breaks can be identified in an enzymatic reaction in two stages: (1) labeling of DNA strand breaks with TdT (Terminal Deoxynucleotidyl Transferase), and (2) incorporation of Fluorescein isothiocyanate (FITC)-dUTP (deoxyuridine triphosphate) into nucleotide polymers. TUNEL-positive sperm stain green and TUNEL-negative samples stain red and it can be directly detected and quantified by fluorescence microscopy. This kit is designed to be a precise, fast, and simple nonradioactive technique to detect and quantify the number apoptotic cells. It is specific as it labels DNA strand breaks generated during apoptosis, which enables the test to discriminate between apoptotic and necrotic cells.

Descriptive statistics will be used to report mean, median and minimum and maxi-mum values for each variable. Exact test for Friedman's test will be used to investigate the presence of differences across the 3 techniques. Exact test for Wilcoxon signed rank test will be used for pairwise comparisons. A Bonferroni correction will be applied to adjust for multiple comparisons. Level of significance is set at p<0.05, 2-tailed. Statistical analysis will be performed by means of STATA 15.1 and SPSS 26.0 (Statistical Package for the Social Sciences). A number of 50 patients will be included in the study.

The results obtained will help to improve the sperm selection process in the IVF laboratory

Medical subject headings
Infertility, Male

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. DNA Fragmentation Index

    percentage of sperm cells with DNA fragmentation out of selected sperm cells

    Measured: 1 year

  2. Progressive Motility Index

    percentage of sperm cells with progressive motility out of selected sperm cells

    Measured: 1 year

  3. Early Apoptosis Index

    percentage of early apoptotic sperm cells out of selected sperm cells

    Measured: 1 year

  4. Normal Morphology Index

    percentage of morphological normal sperm cells out of selected sperm cells

    Measured: 1 year

  5. Concentration

    number of sperm cells per ml of ejaculated semen sample

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2022
  2. Study start16 Jul 2022
  3. Primary completion16 Jan 2023
  4. Study completion1 Aug 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05383599
Sponsor's protocol ID
22114CROSP_IM
Acronym
CROSP
Status last verified
Feb 2023
First submitted
13 May 2022
Last updated
6 Feb 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Male Infertility, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact ileana mateizel (003224776690, ileana.mateizel@uzbrussel.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

DNA Fragmentation Index (time frame: 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in